{"transactions":[{"id":1488547,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Options (obligation to sell)","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":120,"ownership":{"direct":false,"nature":"By BioXcel LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The warrants underlying each call option will be exercisable for common interests in BioXcel LLC at an exercise price per common interest equal to $1,709.88."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"BioXcel LLC has agreed to redeem each common interest in BioXcel LLC acquired pursuant to the exercise of the warrant described in footnote 7 above in exchange for 149.22 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":120,"derivative":{"exercise_date":"2024-06-04","expiration_date":"2026-08-31","underlying":"Common Stock","underlying_shares":17906},"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":1488546,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-05","kind":"sale","planned":false,"acquired":false,"shares":126014,"price":1.5841,"value":199618.7774,"ownership":{"direct":false,"nature":"By BioXcel LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents sales of an amount of shares of Common Stock sufficient to cover certain tax liabilities incurred in connection with the transfers of Common Stock reported herein."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at a per share prices ranging from $1.55 to $1.635. The Reporting Persons undertake to provide upon request of the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":7685501,"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":1488545,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":126014,"price":1.6309,"value":205516.2326,"ownership":{"direct":false,"nature":"By BioXcel LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents sales of an amount of shares of Common Stock sufficient to cover certain tax liabilities incurred in connection with the transfers of Common Stock reported herein."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at a per share prices ranging from $1.605 to $1.68. The Reporting Persons undertake to provide upon request of the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":7811515,"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":1488544,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-05","kind":"sale","planned":false,"acquired":false,"shares":283122,"ownership":{"direct":false,"nature":"By Holdings, Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to certain agreements, BioXcel LLC transferred 566,245 shares of Common Stock to Parent (defined below) and 42,976 shares of Common Stock to certain of its other members, each in exchange for common interests in BioXcel LLC. Subsequently, Parent transferred 566,245 shares of Common Stock to certain of its stockholders in exchange for their interests in Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":1488543,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":283123,"ownership":{"direct":false,"nature":"By Holdings, Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to certain agreements, BioXcel LLC transferred 566,245 shares of Common Stock to Parent (defined below) and 42,976 shares of Common Stock to certain of its other members, each in exchange for common interests in BioXcel LLC. Subsequently, Parent transferred 566,245 shares of Common Stock to certain of its stockholders in exchange for their interests in Parent."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects securities acquired pursuant to a transaction exempt from reporting under Rule 16a-13."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":283122,"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":1488542,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":609221,"ownership":{"direct":false,"nature":"By BioXcel LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to certain agreements, BioXcel LLC transferred 566,245 shares of Common Stock to Parent (defined below) and 42,976 shares of Common Stock to certain of its other members, each in exchange for common interests in BioXcel LLC. Subsequently, Parent transferred 566,245 shares of Common Stock to certain of its stockholders in exchange for their interests in Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":7937529,"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":2651986,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":1,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T17:21:54.000Z","date":"2021-06-25","kind":"sale","acquired":false,"shares":473250,"price":30.8283,"value":14589492.975,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of the Reporting Person. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of the Reporting Person. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":8546750,"source":{"system":"sec-edgar","filing":"0001104659-21-086943","document":"tm2119762-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465921086943/tm2119762-6_4seq1.xml","form_type":"4"}},{"id":2779545,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":1,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T20:21:35.000Z","date":"2020-07-24","kind":"other","acquired":false,"shares":160000,"price":60.76,"value":9721600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On the transaction date, the Reporting Person distributed 160,000 shares of the Issuer's common stock owned directly by it to two of its stockholders in exchange for a proportionate reduction in the number of shares in the Reporting Person owned by such stockholders."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-038559","document":"tm217124-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465921038559/tm217124-10_4seq1.xml","form_type":"4"}},{"id":2779544,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":1,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T20:21:35.000Z","date":"2020-07-24","kind":"other","acquired":true,"shares":160000,"price":60.76,"value":9721600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These securities were acquired as the result of the distribution of the Issuer's common stock by BioXcel LLC to the Reporting Person in exchange for a proportionate reduction in the interest in BioXcel LLC owned by the Reporting Person.  As a result of such distribution, 160,000 shares of common stock were owned directly by the Reporting Person, with the remainder held of record by BioXcel LLC, which is a subsidiary of the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These securities were acquired as the result of the distribution of the Issuer's common stock by BioXcel LLC to the Reporting Person in exchange for a proportionate reduction in the interest in BioXcel LLC owned by the Reporting Person.  As a result of such distribution, 160,000 shares of common stock were owned directly by the Reporting Person, with the remainder held of record by BioXcel LLC, which is a subsidiary of the Reporting Person."}],"balance_after":160000,"source":{"system":"sec-edgar","filing":"0001104659-21-038559","document":"tm217124-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465921038559/tm217124-10_4seq1.xml","form_type":"4"}},{"id":2779543,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":1,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T20:21:35.000Z","date":"2020-07-24","kind":"other","acquired":false,"shares":160000,"price":60.76,"value":9721600.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These securities were acquired as the result of the distribution of the Issuer's common stock by BioXcel LLC to the Reporting Person in exchange for a proportionate reduction in the interest in BioXcel LLC owned by the Reporting Person.  As a result of such distribution, 160,000 shares of common stock were owned directly by the Reporting Person, with the remainder held of record by BioXcel LLC, which is a subsidiary of the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These securities were acquired as the result of the distribution of the Issuer's common stock by BioXcel LLC to the Reporting Person in exchange for a proportionate reduction in the interest in BioXcel LLC owned by the Reporting Person.  As a result of such distribution, 160,000 shares of common stock were owned directly by the Reporting Person, with the remainder held of record by BioXcel LLC, which is a subsidiary of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":9020000,"source":{"system":"sec-edgar","filing":"0001104659-21-038559","document":"tm217124-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465921038559/tm217124-10_4seq1.xml","form_type":"4"}}]}